Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) Director David P. Southwell sold 10,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $24.05, for a total transaction of $240,500.00. Following the completion of the transaction, the director now directly owns 114,784 shares of the company’s stock, valued at $2,760,555.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rocket Pharmaceuticals Price Performance
Shares of RCKT opened at $23.68 on Thursday. The stock has a fifty day moving average of $27.45 and a two-hundred day moving average of $25.27. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.04. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53.
Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.14. During the same period last year, the company earned ($0.92) earnings per share. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.94 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. UBS Group dropped their target price on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a report on Friday, March 1st. StockNews.com raised shares of Rocket Pharmaceuticals to a “sell” rating in a research note on Friday, February 9th. The Goldman Sachs Group began coverage on shares of Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They set a “neutral” rating and a $39.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Rocket Pharmaceuticals in a research note on Tuesday, February 27th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Rocket Pharmaceuticals from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Rocket Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $52.13.
Get Our Latest Stock Report on Rocket Pharmaceuticals
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Read More
- Five stocks we like better than Rocket Pharmaceuticals
- Insider Selling Explained: Can it Inform Your Investing Choices?
- United Airlines Soars on Earnings Beat
- Best Stocks Under $10.00
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is a Special Dividend?
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.